Fujirebio & Randox in cancer assay deal:
This article was originally published in Clinica
Executive Summary
Fujirebio Diagnostics (FDI) is collaborating with UK firm Randox Laboratories on the development of cancer diagnostic assays that will employ FDI's cancer marker antibodies and Randox' automated biochip array technology. Crumlin, Northern Ireland-based Randox' array technology permits the simultaneous determination of a panel of diagnostic markers from just a single patient sample. Multiplexing - using several biomarkers together - may help detect disease at an earlier, more treatable stage, said FDI, of Malvern, Pennsylvania firm (see Clinica No 1018, p 17).
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.